Heartflow, Inc. · NASDAQ:HTFL
Heartflow — SPAC Merger (July 2021)
33 slides from Heartflow's SPAC merger presentation, July 2021
Slide 1: Investor Presentation July 2021
Investor Presentation July 2021
Slide 2: Disclaimer
Disclaimer Disclaimer This presentation is for information purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between HeartFlow Holding, Inc. (“HeartFlow”) and Longview Acquisition Corp. II (“Longvi
Slide 3: Disclaimer (continued)
Disclaimer (continued) Industry and Market Data In this Presentation, Longview and HeartFlow rely on and refer to certain information and statistics obtained from third-party sources which they believe to be reliable. Neither Longview nor HeartFlow has independently verified the accuracy or complete
Slide 4: Today's Presenters
Today’s Presenters Transaction Overview Company Overview Larry Robbins John Stevens, M.D. Charles A. Taylor, Ph.D. Chairman President & CEO, Co-founder Founder, Chief Technology Officer Longview Acquisition Corp. II HeartFlow HeartFlow Amp Resources 4
Slide 5: Transaction Overview
Transaction Overview HeartFlow is preparing to go public through a SPAC Merger with Longview Acquisition Corp. II • HeartFlow Holding, Inc. (“HeartFlow”) is revolutionizing precision “heart care” with non-invasive personalized cardiac tests and enterprise software suite solutions, which provide unpr
Slide 6: Transaction Overview
Transaction Overview ($ in mm, except per share values) Key Highlights Sources Uses • HeartFlow will be appropriately capitalized with ~$400mm of Equity to HeartFlow Stockholders $2,150.0 Equity to HeartFlow Stockholders $2,150.0 net cash (assuming no redemptions) post-closing Longview Cash Held in
Slide 7: HeartFlow Met Every Longview Criteria
HeartFlow Met Every Longview Criteria • Address a Significant, Unmet Medical Need • Heart disease is #1 cause of death • Largest component of chronic health spend • Current imaging standard of care is fundamentally flawed 60+ targets reviewed • Proprietary, Innovative Technology With Significant I
Slide 8: Executive Summary
Executive Summary 1• Driven by a mission to improve cardiovascular care for patients, physicians, providers and payers… • 2 Addressing the number one cause of death and largest component of chronic health spend… • 3 HeartFlow developed and introduced a revolutionary precision “heart care” technology
Slide 9: Driven by a Mission to Improve Cardiovascular Care
121 Driven by a Mission to Improve Cardiovascular Care for Patients, Physicians, Providers and Payers 9
Slide 10: Addressing the Number One Cause of Death and Largest Component of Chronic Health Spend
2 Addressing the Number One Cause of Death and Largest Component of Chronic Health Spend More than twice as many 1 out of every 3 1 billion people in the world at deaths as the 2nd most deaths moderate to high risk today common cause (cancer) Center for Health Metrics and Evaluation Cardiovascular D
Slide 11: The Status Quo Heart Disease Care Pathway is Suboptimal
3 The “Status Quo” Heart Disease Care Pathway Dominated by Echo & Nuclear Stress Testing is Suboptimal Non-invasive Testing Invasive Testing Risk Assessment 10M non-invasive tests in 2M+ catheterizations in the US alone every year the US alone every year3 Multiple possible Multiple layers starting p
Slide 12: HeartFlow Developed a Revolutionary Precision Heart Care Technology
3 HeartFlow Developed and Introduced a Revolutionary Precision “Heart Care” Technology that Disrupts the Status Quo HeartFlow’s product suite leverages and builds upon a foundational technology platform Precision Diagnostics Optimization of Therapy Informed Clinical Coronary Computed Decision Tomogr
Slide 13: Empowering Physicians with an AI-enabled, Cloud-based Enterprise Software Suite
4 Empowering Physicians with an AI-enabled, Cloud-based Enterprise Software Suite • AI-powered modeling of all coronary arteries ADVANCED TECH • Highest diagnostic accuracy driven by big data analytics • Compliant cloud computing to protect sensitive data • Secure bi-directional data transmission to
Slide 14: Transforming Cardiovascular Disease Risk Assessment, Diagnosis, Planning, and Treatment Management
5 Transforming Cardiovascular Disease Risk Assessment, Diagnosis, Planning, and Treatment Management Risk Assessment Monitoring Precision Diagnostics Optimization of Therapy (Prevention) (Pre or Post Treatment) Risk Score for PreRead* FFRCT Planner Asymptomatic Patients* CABG Plaque* FFRCT Planning*
Slide 15: Delivering Precise, Personalized and Enhanced Care Decisions for Patients
6 Delivering Precise, Personalized and Enhanced Care Decisions for Patients Monitor Assess • Ongoing patient monitoring coupled with • The historical path to diagnosing CAD is patient history ensures physicians and unclear, unreliable, insufficient and patients will remain vigilant about CAD ineffec
Slide 16: AGE: 60 68. SEX: SEX:
AGE:60 AGE: 68. SEX: SEX: MALE MALE HISTORY:SYMPTOMATIC, HISTORY: ASYMPTOMATIC, FAMILY FAMILY HISTORY HISTORY OF OF HEART HEART DISEASE DISEASE *Currentlyinindevelopment developmentand andnot notavailable availablefor forclinical clinicaluse. use. 16 *Currently 16
Slide 17: Providing Significant Clinical Evidence
7 Providing Significant Clinical Evidence Since inception, HeartFlow has been committed to producing comprehensive clinical evidence to substantiate the diagnostic accuracy, safety, efficacy, cost-effectiveness, and utility of its product portfolio ROBUST EVIDENCE ≫ 16 company-sponsored clinical tri
Slide 18: Leveraging a Strong Intellectual Property Portfolio
7 Leveraging a Strong Intellectual Property Portfolio HeartFlow’s differentiated IP portfolio provides a powerful competitive advantage, while a significant imaging database fuels an AI-based technology roadmap to drive incremental automated product enhancements 400+ 15 Million+ Annotated CT Images
Slide 19: Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers
8 Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers HeartFlow has unlocked key barriers to adoption of their technology offering Technology & Experienced, diverse management team with relevant tech and cardiology backgrounds Healthcare Competency Clinical Evidenc
Slide 20: Unlocked Barriers Driving Adoption: Cardiology Society Recognition
8 Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers The CTA + HeartFlow pathway is recognized by key cardiology societies Multimodality Cardiovascular Imaging in the Midst of COVID-19 Pandemic “CTA can be used to rapidly evaluate multiple forms of cardiac disease”
Slide 21: Unlocked Barriers Driving Adoption: Hospitals and Payers
8 Unlocked Barriers Driving Adoption by Key Cardiology Societies, Providers and Payers The CTA + HeartFlow pathway is trusted by leading US hospitals and has been prioritized by US payers 80% of the Top 50 Heart Hospitals1 96% in the US Have Adopted HeartFlow US commercial lives covered System-Wide
Slide 22: Aligned With and Enabling of Healthcare's Mega Trends
9 Aligned With and Enabling of Healthcare’s Mega Trends HeartFlow is the definition of value-based care Value-Based Care Universal Access We believe the true way to deliver “better” healthcare while reducing costs is to equip clinicians with superior technology that fundamentally informs better care
Slide 23: Predictable and Attractive SaaS Model Combining Fee-per-analysis and Base Subscription Layers
10 Predictable and Attractive SaaS Model Combining Fee-per-analysis and Base Subscription Layers Historically successful business model incorporates hybrid approach of fee-per-analysis (consumption based at a fixed per test rate) and enterprise software suite subscription (annual bundled contract) R
Slide 24: Augmented by a Robust Software Pipeline to Fuel a Significant TAM
11 Augmented by a Robust Software Pipeline to Fuel a Significant TAM HeartFlow is developing a comprehensive, integrated cloud-based heart care technology product suite to help physicians make more optimal cardiovascular care decisions Plaque Myocardial FFRCT Planner PreRead Analysis Insights Anatom
Slide 25: From a Fraction of a Fraction to a Majority of a Majority
11 Augmented by a Robust Software Pipeline to Fuel a Significant TAM From a fraction of a fraction to a majority of a majority • Over the coming 15 years, we envision HeartFlow moving from a small minority of coronary CTA scans to being attached to the vast majority • Additionally, over the same per
Slide 26: Clear Development Path to Grow TAM from $10B to $50B+
11 Augmented by a Robust Software Pipeline to Fuel a Significant TAM HeartFlow has a clear projected development path to grow TAM from $10B to $50B+ Illustrative HeartFlow TAM Evolution1 Today Near Term Medium Term Long Term Symptomatic HeartFlow Risk Assessment $24.0B Asymptomatic / Preventative Ac
Slide 27: Fueling a High Growth Outlook
12 Fueling a Compelling High Growth Outlook Management believes that HeartFlow’s financial forecast is supported by a highly predictable and leverageable business model with a robust commercial pipeline, favorable industry tailwinds, and no customer churn 2021-2025 Plan Key Growth Drivers 1. New cus
Slide 28: Brought to the Market at an Attractive Valuation
13 Brought to the Market at an Attractive Valuation HeartFlow and Longview II believe HeartFlow is priced at a significant discount to the relevant comp sets despite offering materially faster revenue growth and superior margin prospects Revenue CAGR1,2 EV/Revenue1,2 % Gross Margin1,2 ’21E-’23E ’21E
Slide 29: Led by a Strong Team
14 Led by a Strong Team Leadership Team Senior Team John Stevens, M.D.* William C. Weldon* Heather Brown Tim Fonte President & CEO, Co-founder Board Chair SVP, Market Access & SVP, Customer Success Heartport, Amp Resources, Stanford Former Chairman & CEO, J&J Reimbursement Stanford University, Camer
Slide 30: Fortified by Experienced Investment Partners
15 Fortified by Experienced Investment Partners Larry Robbins – Chairman, Longview Acquisition Corp. II • Longview II is sponsored by an affiliate of Glenview Capital Management, a registered investment adviser • CEO and Founder of Glenview Capital Management • Board Chair: KIPP NY Inc. • Glenview b
Slide 31: Existing HeartFlow Investor Base
15 Fortified by Experienced Investment Partners Existing HeartFlow Investor Base 31
Slide 32: Enabling Access to Optimized Care for All Patient Populations
16 Enabling Access to Optimized Care for All Patient Populations Investors’ collective investment and partnership with HeartFlow will achieve meaningful societal goals HeartFlow’s Technical Strengths Societal & Commercial Opportunity Disruptive, Best-in-class Improve Diagnostic Accuracy Robust Intel
Slide 33: Thank You!
Tnank You! O HeartFlow’